11 Form 4 filings for SCTX between 2026-07-27 and 2026-07-29, from 9 filers. 11 discretionary (0 sales, 5 purchases). 4 of 11 state a filing-level total, summing to $66,299,751; the rest report only their largest transaction, so the true figure is higher. Prices ran $15 to $15.
| Filed | Filer | Role | Action | Shares largest txn | Price | Filing total | Txns |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | AH Equity Partners Bio III, L.L.C. | — | 2,051,742 | — | — | 3 | |
| 2026-07-29 | GORDON CARL L | purchased (open market) | 1,000,000 | $15.00 | $15,000,000 | 2 | |
| 2026-07-29 | OrbiMed Capital GP VIII LLC | purchased (open market) | 1,000,000 | $15.00 | $15,000,000 | 2 | |
| 2026-07-28 | Avoro Ventures LLC | See Remarks | purchased (open market) | 2,333,333 | $15.00 | $36,259,761 | 3 |
| 2026-07-27 | Lucas Svetlana | purchased | 3,000 | $15.00 | — | — | |
| 2026-07-27 | Oakes Benjamin L. (President, CEO at Scribe Therapeutics, Inc.) filed a Form 4; no parseable transaction details were found in the filing. | ||||||
| 2026-07-27 | GORDON CARL L (Director at Scribe Therapeutics, Inc.) filed a Form 4; no parseable transaction details were found in the filing. | ||||||
| 2026-07-27 | Watson James Dean (Director at Scribe Therapeutics, Inc.) filed a Form 4; no parseable transaction details were found in the filing. | ||||||
| 2026-07-27 | Bleharski Joshua (Director at Scribe Therapeutics, Inc.) filed a Form 4; no parseable transaction details were found in the filing. | ||||||
| 2026-07-27 | Parrot David | Chief Financial Officer | purchased (open market) | 1,333 | $15.00 | $39,990 | 2 |
| 2026-07-27 | Aghazadeh Behzad (See Remarks at Scribe Therapeutics, Inc.) filed a Form 4; no parseable transaction details were found in the filing. | ||||||
| 11 filings · 9 filers · disclosed totals only | $66,299,751 (4/11) | — | |||||